Curasight A/S
Nic Gillings is a highly experienced Chief Radiochemist at Copenhagen University Hospital, Rigshospitalet, a position held since April 2001. Prior to this role, Nic served as a Radiochemist at the PET Centre of Århus University Hospital, Denmark, from 1994 to 2001, and at the Clinical PET Centre, St. Thomas' Hospital, London, from August 1992 to August 1994. Nic's academic background includes a Ph.D. in PET Radiochemistry from the University of London, earned between 1993 and 1998, an M.Phil. in Chemistry from The University of Sheffield from 1990 to 1992, and a B.Sc. (Special Honours) in Chemistry from The University of Sheffield from 1987 to 1990.
This person is not in any teams
Curasight A/S
Curasight is a biotech company focused on addressing the need for improved diagnosis and treatment of several cancer indications. The Company has developed a highly specific PET (Positron emission tomography) imaging ligand, uTRACE®, targeting the receptor uPAR, which is a biomarker only expressed in cancer. uTRACE® will become a game-changer inthe diagnosis and treatment of cancer patients.In addition, with the promising results obtained within diagnostics Curasight will also pursues uPAR targeted radionuclide therapy using the uTREAT® ligand. As PET imaging and radionuclide therapy is based on the same uPAR binding peptide, a uTRACE® scan can precisely predict where subsequent targeted radiation therapy will be delivered. uTRACE® covers the diagnostic path and uTREAT® covers the therapy. This will be the new management and treatment of cancer patients in the future.